The HeartMate 3™ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years, our LVAD device technology is making a better future possible for many patients with advanced heart failure.*1-3 The HeartMate 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.1
The Full MagLev Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.
HeartMate 3 LVAD with Full MagLev Flow Technology Pump offers:
The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.
The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
There are comprehensive clinical evidence materials available to learn about the survival rate and patient improvement associated with the HeartMate 3 LVAD. For a deep dive into the clinical data, visit the Clinical Evidence and Momentum 3 Trial information.
MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.**1
The ELEVATE Registry7 evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting. 5-year extended follow-up showed:
Our coding and reimbursement documents provide information about coverage, coding and payment, economic insights and supporting documentation for Abbott LVAD and mechanical circulatory support products.
On December 1, 2020, the Centers for Medicare and Medicaid Services (CMS) updated the final decision memo for National Coverage Determination (NCD 20.9.1) for Ventricular Assist Devices.
CMS removed the pre-implant designations (bridge-to-transplant and destination therapy) in favor of central clinical criteria for qualification of VADs for the purpose of coverage and payment effective for dates of services on and after December 1, 2020.
To access the final decision memo and the analysis in its entirety please go to cms.gov.
For the full resource list, visit Reimbursement & Coding for left ventricular assist devices.
*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
**HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
§For a continuous-flow LVAD in a randomized controlled trial.